A week into his tenure as head of the FDA’s Center for Drug Evaluation and Research, experts agree that Rick Pazdur is the “ideal fit” to stabilize the agency. And, according to one ex-FDA official, ...

In a surprise move, the FDA has named the longtime leader of its oncology department, Richard Pazdur, M.D., as the new ...

The appointment of Richard Pazdur, currently director of the FDA’s Oncology Center of Excellence, comes less than a week ...

The FDA on Nov. 11 appointed Richard Pazdur, MD, as the new director of the Center for Drug Evaluation and Research.Pazdur ...

High-ranking FDA official George Tidmarsh, M.D., Ph.D., has tendered his resignation after an unconventional LinkedIn diatribe landed the senior drug regulator at the center of a lawsuit and an ...

The U.S. FDA once again has a leadership gap at the top of its drug center, which already has been ravaged this year by massive terminations, resignations and retirements of senior leaders. George ...

"FDA’s revolving door reveals Pazdur as new CDER head" was originally created and published by Clinical Trials Arena, a ...

The FDA on Tuesday announced 26-year agency veteran Richard Pazdur will replace a top regulator who resigned earlier this month amid accusations of abusing his power. Pazdur will be the director of ...

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. Adam Feuerstein is a senior ...

The U.S. FDA once again has a leadership gap at the top of its drug center. George Tidmarsh, a biopharma industry veteran who’s helmed CDER for a little more than three months, resigned yesterday ...

KS, has introduced The Better Food Disclosure Act (The Better FDA), a to reform the “Generally Recognized as Safe” or “GRAS” ...

The Food and Drug Administration (FDA) defied the advice of its own drug safety experts to warn pregnant women about Tylenol for nearly a decade, internal reports and presentations obtained by the ...